Add to ORKGBackground. Essential thrombocythemia (ET) and primary myelofibrosis (MF) are myeloproliferative neoplasms characterized by the overproduction of mature cells such as platelets (ET) or early bone marrow fibrosis due to scarring induced by highly proliferating myeloid progenitors and pathological stimulation of local fibroblasts (MF). Somatic mutations in CALR gene have recently identified in the majority of JAK2-V617F and MPL negative ET and MF patients. In this study we evaluated the frequency and type of CALR mutations and their clinical and hematological features. Methods. A total of 54 patients, 29 ET and 25 MF patient, was included in this study. All patients were JAK2 V617F and MPL negative. We registered clinical and hematolo...
In myeloproliferative neoplasms (MPN), JAK2V617F allele burden measurement has an impact on prognosi...
Somatic mutations in CALR gene have been reported in 60%–88% of patients with essential thrombocythe...
AbstractInsertion and/or deletion mutations of the CALR gene have recently been demonstrated to be t...
Introduction. JAK2V617F mutation is detected in approximately 50 % of patients with essential thromb...
Polycythemia vera (PV) and essential thrombocythemia (ET) are Philadelphia-negative myeloproliferati...
Mutations in the gene calreticulin (CALR) were recently discovered in 60-80% of patients (pts) with ...
Background: Recent advances in BCR-ABL1-negative myeloproliferative neoplasms (MPN) have highlighted...
The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and the Calreticulin (CALR...
Somatic CALR mutations occur in approximately 70% of patients with JAK2 V617F-negative essential thr...
Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be the secon...
Somatic mutations in the CALR gene have been recently identified as acquired alterations in myelopro...
Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative ...
Calreticulin (CALR) mutations were recently described in JAK2 and MPL unmutated primary myelofibrosi...
The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and calreticulin (CALR) mu...
BACKGROUND: Approximately 50 to 60% of patients with essential thrombocythemia or primary myelofi...
In myeloproliferative neoplasms (MPN), JAK2V617F allele burden measurement has an impact on prognosi...
Somatic mutations in CALR gene have been reported in 60%–88% of patients with essential thrombocythe...
AbstractInsertion and/or deletion mutations of the CALR gene have recently been demonstrated to be t...
Introduction. JAK2V617F mutation is detected in approximately 50 % of patients with essential thromb...
Polycythemia vera (PV) and essential thrombocythemia (ET) are Philadelphia-negative myeloproliferati...
Mutations in the gene calreticulin (CALR) were recently discovered in 60-80% of patients (pts) with ...
Background: Recent advances in BCR-ABL1-negative myeloproliferative neoplasms (MPN) have highlighted...
The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and the Calreticulin (CALR...
Somatic CALR mutations occur in approximately 70% of patients with JAK2 V617F-negative essential thr...
Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be the secon...
Somatic mutations in the CALR gene have been recently identified as acquired alterations in myelopro...
Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative ...
Calreticulin (CALR) mutations were recently described in JAK2 and MPL unmutated primary myelofibrosi...
The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and calreticulin (CALR) mu...
BACKGROUND: Approximately 50 to 60% of patients with essential thrombocythemia or primary myelofi...
In myeloproliferative neoplasms (MPN), JAK2V617F allele burden measurement has an impact on prognosi...
Somatic mutations in CALR gene have been reported in 60%–88% of patients with essential thrombocythe...
AbstractInsertion and/or deletion mutations of the CALR gene have recently been demonstrated to be t...